AZTA

Azenta, Inc. (AZTA) | Rumor.io

Azenta

AZTA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,878

Bullish sentiment (50-day avg)0%

Price to earnings ratio31.7

Market capitalization1.5B

Earnings per share-2.46

Dividend yield (TTM)1.17%

Revenue (annual)593.8M

Net income (annual)-55.8M

Social

What share of all stock conversation is about AZTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 1

Azenta, Inc. (AZTA) has seen a 17% increase since this post, and a 43% increase since buying the stock after earnings.
The $30 call option for AZTA on 17 JUL 26 has a price of $0.50.
The author is using a "gap fill play" strategy for AZTA, citing sector sentiment, relative strength, and high confidence.

Generated by AI

Sentiment

Of the messages about AZTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% 0	93.79% +1.12
Bearish	—	—	100% 0	6.21% -1.12

Bullish· Nov 15

Azenta, Inc. (AZTA) has beaten Q4 EPS and sales estimates, with a 15% reduction in share count expected over the next 12 months.
The company has announced a $1.5 billion share repurchase program, with $1 billion to be accelerated over the next year, and a 30% revenue growth expectation.
Azenta's price target has been raised to $78 by Needham analyst David Saxon, with a buy rating maintained.

Bearish· Aug 28

The asset's price may be due for a correction, potentially dropping to $36 or lower, as volume returns to normal.
The company's revenue is expected to decline, which could lead to a significant drop in the asset's value.
The asset's recent price surge may be a result of a pump, and it could soon experience a 30-40 cent dump, potentially breaking below $39.15.

Generated by AI

Topics

Of the messages about AZTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	57.14%	69.48%
Technical Analysis	—	100%	42.86%	5.11%
Analysts	—	0%	0%	1.28%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	24.14%
Macro	—	0%	0%	0%

Nov 13

Azenta, Inc. reported Q4 and FY23 results, with revenue of $172M, up 25% YoY, and net income of $0.05 EPS.
The company announced an agreement with the Democratic Republic of the Congo's Ministry of Public Health, Hygiene and Prevention for a significant national universal health project, with B Medical Systems delivering a complete solution for vaccine storage and transport.
Azenta also announced plans to repurchase an additional $500M in shares in FY24, with a strong balance sheet position and ample liquidity, and expects to achieve organic revenue growth of 5-8% in FY24.

Generated by AI

Community

Of the messages about AZTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	7.43%
Newcomers	—	100%	100%	92.57%

Regulars· Nov 14

Azenta, Inc.'s Q4 2023 earnings report showed a significant increase in revenue, with a 25% year-over-year growth to $172M, and a notable EPS of $0.13, surpassing the expected $0.02.
The company's fiscal year guidance indicates a projected EPS of $0.19-0.29, and revenue of $696-718M, which is slightly below the previous year's $705.6M.
Azenta, Inc.'s stock price has seen a notable increase, with a 12.91% and 13.89% rise in two separate instances of above-average trading volume, with the latter being 201% above average.

Newcomers· Nov 21

Azenta's Q4 results exceeded expectations, with adj. EPS of $0.21, revenue of $159M, and net income of $47.1M, indicating profitable growth and margin expansion.
The company's better-than-expected earnings and solid revenue growth have driven a strong stock performance, with a clear bullish reversal and potential for a sustained uptrend.
Azenta's positive Q4 earnings report and guidance for 2026 are seen as the clearest positive catalysts for the company in recent months, confirming a period of margin expansion and moderate growth.

Generated by AI

News

Azenta formalizes interim CEO pay and retention grants

Detailed price information for Azenta Inc (AZTA-Q) from The Globe and Mail including charting and trades.

11d agoThe Globe and Mail

Azenta sets compensation terms for interim CEO and grants executive retention awards

12d agoInvesting.com

Q2 Earnings Review: Drug Development Inputs & Services Stocks Led by Azenta (NASDAQ:AZTA)

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta (NASDAQ:AZTA) and its peers.

15d agoYahoo Finance

Azenta Completes B Medical Divestiture With Loan Repayment

Detailed price information for Azenta Inc (AZTA-Q) from The Globe and Mail including charting and trades.

24d agoThe Globe and Mail

Azenta completes B Medical sale as vendor loan repaid (AZTA)

25d agoseekingalpha.com

Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems

26d agoYahoo Finance

Also Discussed

Investors talking about AZTA also mention

#	Name	Attention
1	Twist Bioscience CorporationTWST	0%-0.02
2	BioLife Solutions Inc.BLFS	0%0
3	Surgery Partners Inc.SGRY	0%0
4	Evolent Health IncEVH	0%0
5	FOLD - Amicus Therapeutics, Inc.	——
6	MKS Inc.MKSI	0%+0
7	Progyny IncPGNY	0%0
8	Rockwell Automation Inc.ROK	0%0
9	The Timken CompanyTKR	0%0
10	Entegris Inc.ENTG	0%0

Azenta, Inc.

Healthcare
Medical Instruments & Supplies

Azenta, Inc. is a life sciences tools and services company focused on sample management, biostorage, and genomic services. The company provides automated storage systems, temperature-controlled logistics, laboratory consumables, informatics, and repository services that help customers preserve, track, and manage biological and chemical samples across research, clinical development, and commercialization workflows. Azenta also offers sequencing, gene synthesis, and related multiomics services for pharmaceutical, biotechnology, academic, and healthcare customers. Its solutions are used to support drug development, clinical research, advanced therapies, and biospecimen handling, making the company an important provider of infrastructure for sample integrity and data-driven life sciences operations. Azenta is headquartered in Burlington, Massachusetts, and serves a global customer base across North America, Europe, and Asia.

Website

Location

200 Summit Drive

Burlington, MA, 01803

United States

Social

What share of all stock conversation is about AZTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 1

Azenta, Inc. (AZTA) has seen a 17% increase since this post, and a 43% increase since buying the stock after earnings.
The $30 call option for AZTA on 17 JUL 26 has a price of $0.50.
The author is using a "gap fill play" strategy for AZTA, citing sector sentiment, relative strength, and high confidence.

Generated by AI

Sentiment

Of the messages about AZTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% 0	93.79% +1.12
Bearish	—	—	100% 0	6.21% -1.12

Bullish· Nov 15

Azenta, Inc. (AZTA) has beaten Q4 EPS and sales estimates, with a 15% reduction in share count expected over the next 12 months.
The company has announced a $1.5 billion share repurchase program, with $1 billion to be accelerated over the next year, and a 30% revenue growth expectation.
Azenta's price target has been raised to $78 by Needham analyst David Saxon, with a buy rating maintained.

Bearish· Aug 28

The asset's price may be due for a correction, potentially dropping to $36 or lower, as volume returns to normal.
The company's revenue is expected to decline, which could lead to a significant drop in the asset's value.
The asset's recent price surge may be a result of a pump, and it could soon experience a 30-40 cent dump, potentially breaking below $39.15.

Generated by AI

Topics

Of the messages about AZTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	57.14%	69.48%
Technical Analysis	—	100%	42.86%	5.11%
Analysts	—	0%	0%	1.28%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	24.14%
Macro	—	0%	0%	0%

Nov 13

Azenta, Inc. reported Q4 and FY23 results, with revenue of $172M, up 25% YoY, and net income of $0.05 EPS.
The company announced an agreement with the Democratic Republic of the Congo's Ministry of Public Health, Hygiene and Prevention for a significant national universal health project, with B Medical Systems delivering a complete solution for vaccine storage and transport.
Azenta also announced plans to repurchase an additional $500M in shares in FY24, with a strong balance sheet position and ample liquidity, and expects to achieve organic revenue growth of 5-8% in FY24.

Generated by AI

Community

Of the messages about AZTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	7.43%
Newcomers	—	100%	100%	92.57%

Regulars· Nov 14

Azenta, Inc.'s Q4 2023 earnings report showed a significant increase in revenue, with a 25% year-over-year growth to $172M, and a notable EPS of $0.13, surpassing the expected $0.02.
The company's fiscal year guidance indicates a projected EPS of $0.19-0.29, and revenue of $696-718M, which is slightly below the previous year's $705.6M.
Azenta, Inc.'s stock price has seen a notable increase, with a 12.91% and 13.89% rise in two separate instances of above-average trading volume, with the latter being 201% above average.

Newcomers· Nov 21

Azenta's Q4 results exceeded expectations, with adj. EPS of $0.21, revenue of $159M, and net income of $47.1M, indicating profitable growth and margin expansion.
The company's better-than-expected earnings and solid revenue growth have driven a strong stock performance, with a clear bullish reversal and potential for a sustained uptrend.
Azenta's positive Q4 earnings report and guidance for 2026 are seen as the clearest positive catalysts for the company in recent months, confirming a period of margin expansion and moderate growth.

Generated by AI

Azenta

Social

Jul 1

Bullish· Nov 15

Bearish· Aug 28

Nov 13

Regulars· Nov 14

Newcomers· Nov 21

Azenta formalizes interim CEO pay and retention grants

Azenta sets compensation terms for interim CEO and grants executive retention awards

Q2 Earnings Review: Drug Development Inputs & Services Stocks Led by Azenta (NASDAQ:AZTA)

Azenta Completes B Medical Divestiture With Loan Repayment

Azenta completes B Medical sale as vendor loan repaid (AZTA)

Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems

Also Discussed

Azenta, Inc.

Company Information

Location

Azenta formalizes interim CEO pay and retention grants

Azenta sets compensation terms for interim CEO and grants executive retention awards

Q2 Earnings Review: Drug Development Inputs & Services Stocks Led by Azenta (NASDAQ:AZTA)

Azenta Completes B Medical Divestiture With Loan Repayment

Azenta completes B Medical sale as vendor loan repaid (AZTA)

Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems

Also Discussed

Social

Jul 1

Bullish· Nov 15

Bearish· Aug 28

Nov 13

Regulars· Nov 14

Newcomers· Nov 21